Cargando…

Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression

The present randomized, double blind, parallel group, controlled, multi-centric trial was designed to evaluate the efficacy and tolerability of escitalopram in comparison with citalopram and sertraline in the treatment of major depressive disorder. Outpatients (N=214) with an ongoing/newly diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales: Lalit, Vaya, Appaya, Prakash M., Hegde, Rajendra P., Mital, Anukant K., Mittal, Sunil, Nagpal, Rajesh, Palaniappun, Vaiapuri, Ramsubramaniam, C., Rao, Gundugurti P., Roy, Krishna, Trivedi, Jitendra K., Vankar, Ganpat K., Karan, Rajesh S., Shah, Sweety, Patel, Ronak B.
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950952/
https://www.ncbi.nlm.nih.gov/pubmed/21206792
_version_ 1782187671900127232
author Lalit, Vaya
Appaya, Prakash M.
Hegde, Rajendra P.
Mital, Anukant K.
Mittal, Sunil
Nagpal, Rajesh
Palaniappun, Vaiapuri
Ramsubramaniam, C.
Rao, Gundugurti P.
Roy, Krishna
Trivedi, Jitendra K.
Vankar, Ganpat K.
Karan, Rajesh S.
Shah, Sweety
Patel, Ronak B.
author_facet Lalit, Vaya
Appaya, Prakash M.
Hegde, Rajendra P.
Mital, Anukant K.
Mittal, Sunil
Nagpal, Rajesh
Palaniappun, Vaiapuri
Ramsubramaniam, C.
Rao, Gundugurti P.
Roy, Krishna
Trivedi, Jitendra K.
Vankar, Ganpat K.
Karan, Rajesh S.
Shah, Sweety
Patel, Ronak B.
author_sort Lalit, Vaya
collection PubMed
description The present randomized, double blind, parallel group, controlled, multi-centric trial was designed to evaluate the efficacy and tolerability of escitalopram in comparison with citalopram and sertraline in the treatment of major depressive disorder. Outpatients (N=214) with an ongoing/newly diagnosed ICD-10 major depressive episode and a Hamilton Rating Scale for Depression (HAM-D) score of > 18 were randomly assigned to citalopram, 20–40 mg/day (74 patients), escitalopram, 10–20 mg/day (69 patients) and sertraline, 50-150 mg/day (71 patients), for a 4-week double-blind treatment period, with dosage adjustment (after 2 weeks of treatment) according to the response to treatment. Clinical response was evaluated by the 17 items HAM-D and the Clinical Global Impression (CGI) scales, which were recorded at baseline and at weekly intervals. Tolerability was evaluated by observed/spontaneously reported adverse changes in laboratory parameters (baseline and after 4 weeks). Response rate was defined as a decrease in HAM-D score by 50% from baseline and remission rate was defined as a HAM-D score of < 8. Response rate at the end of two week were 58% for escitalopram (10mg/day), 49% for citalopram (20mg/day) and 52% for sertraline (50-100mg/day). Response rate at the end of four week were 90% for escitalopram (10-20mg/day), 86% for citalopram (20-40mg/day) and 97% for sertraline (100-150mg/day). The Remission rates at the end of four weeks were 74% for escitalopram, 65% for citalopram and 77% for sertraline. Adverse experiences were reported by 45% of patients in escitalopram group, 58% patients in citalopram and 56% patients in the sertraline group. Additionally, there were lesser dropouts and lesser requirement for dose escalation in escitalopram than in citalopram and sertraline group. In conclusion Escitalopram, the Senantiomer of the citalopram is a safe and effective antidepressant in the Indian population. It has potentially superior efficacy than citalopram and a comparable efficacy to sertraline with fewer side effects than both citalopram and sertraline.
format Text
id pubmed-2950952
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-29509522011-01-04 Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression Lalit, Vaya Appaya, Prakash M. Hegde, Rajendra P. Mital, Anukant K. Mittal, Sunil Nagpal, Rajesh Palaniappun, Vaiapuri Ramsubramaniam, C. Rao, Gundugurti P. Roy, Krishna Trivedi, Jitendra K. Vankar, Ganpat K. Karan, Rajesh S. Shah, Sweety Patel, Ronak B. Indian J Psychiatry Original Article The present randomized, double blind, parallel group, controlled, multi-centric trial was designed to evaluate the efficacy and tolerability of escitalopram in comparison with citalopram and sertraline in the treatment of major depressive disorder. Outpatients (N=214) with an ongoing/newly diagnosed ICD-10 major depressive episode and a Hamilton Rating Scale for Depression (HAM-D) score of > 18 were randomly assigned to citalopram, 20–40 mg/day (74 patients), escitalopram, 10–20 mg/day (69 patients) and sertraline, 50-150 mg/day (71 patients), for a 4-week double-blind treatment period, with dosage adjustment (after 2 weeks of treatment) according to the response to treatment. Clinical response was evaluated by the 17 items HAM-D and the Clinical Global Impression (CGI) scales, which were recorded at baseline and at weekly intervals. Tolerability was evaluated by observed/spontaneously reported adverse changes in laboratory parameters (baseline and after 4 weeks). Response rate was defined as a decrease in HAM-D score by 50% from baseline and remission rate was defined as a HAM-D score of < 8. Response rate at the end of two week were 58% for escitalopram (10mg/day), 49% for citalopram (20mg/day) and 52% for sertraline (50-100mg/day). Response rate at the end of four week were 90% for escitalopram (10-20mg/day), 86% for citalopram (20-40mg/day) and 97% for sertraline (100-150mg/day). The Remission rates at the end of four weeks were 74% for escitalopram, 65% for citalopram and 77% for sertraline. Adverse experiences were reported by 45% of patients in escitalopram group, 58% patients in citalopram and 56% patients in the sertraline group. Additionally, there were lesser dropouts and lesser requirement for dose escalation in escitalopram than in citalopram and sertraline group. In conclusion Escitalopram, the Senantiomer of the citalopram is a safe and effective antidepressant in the Indian population. It has potentially superior efficacy than citalopram and a comparable efficacy to sertraline with fewer side effects than both citalopram and sertraline. Medknow Publications 2004 /pmc/articles/PMC2950952/ /pubmed/21206792 Text en Copyright: © Indian Journal of Psychiatry http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lalit, Vaya
Appaya, Prakash M.
Hegde, Rajendra P.
Mital, Anukant K.
Mittal, Sunil
Nagpal, Rajesh
Palaniappun, Vaiapuri
Ramsubramaniam, C.
Rao, Gundugurti P.
Roy, Krishna
Trivedi, Jitendra K.
Vankar, Ganpat K.
Karan, Rajesh S.
Shah, Sweety
Patel, Ronak B.
Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression
title Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression
title_full Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression
title_fullStr Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression
title_full_unstemmed Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression
title_short Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression
title_sort escitalopram versus citalopram and sertraline: a double-blind controlled, multi-centric trial in indian patients with unipolar major depression
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950952/
https://www.ncbi.nlm.nih.gov/pubmed/21206792
work_keys_str_mv AT lalitvaya escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression
AT appayaprakashm escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression
AT hegderajendrap escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression
AT mitalanukantk escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression
AT mittalsunil escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression
AT nagpalrajesh escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression
AT palaniappunvaiapuri escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression
AT ramsubramaniamc escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression
AT raogundugurtip escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression
AT roykrishna escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression
AT trivedijitendrak escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression
AT vankarganpatk escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression
AT karanrajeshs escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression
AT shahsweety escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression
AT patelronakb escitalopramversuscitalopramandsertralineadoubleblindcontrolledmulticentrictrialinindianpatientswithunipolarmajordepression